Status:
ACTIVE_NOT_RECRUITING
Microbiome Characterization in Fatty Pancreas
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Fatty Pancreas
Microbiome Analysis
Eligibility:
All Genders
18+ years
Brief Summary
There has been a growing interest in evaluating the role of gut and intra-lesional microbiome in the pathogenesis of various benign and malignant conditions of the GI tract, liver and pancreas. In add...
Detailed Description
Fatty pancreas (FP) is a pathological metabolic condition characterized by excessive intra-pancreatic fat deposition (IPFD). FP is an increasingly recognized metabolic condition with a prevalence of 1...
Eligibility Criteria
Inclusion
- Age 18 or older
- Patients with FP, defined by MRI-PDFF pancreatic fat fraction \> 6.2%
- Patients who are able to provide written informed consent to participate in the study.
Exclusion
- Unable to provide written informed consent
- Recent use of antibiotic, prebiotic, probiotic and symbiotic
- Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
Key Trial Info
Start Date :
April 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06938646
Start Date
April 14 2025
End Date
June 30 2026
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital, The Chinese University of Hong Kong
Shatin, New Territories, Hong Kong